Unlocking the Potential of Life Sciences in 2024
Navigating Capital-Raising, M&A Prospects, and Transformative Trends in the Life Sciences Industry
As we gear up for the annual J.P. Morgan Healthcare Conference, attendees are hoping to strike fruitful conversations with other dealmakers regarding capital-raising and M&A prospects, aided by the backdrop of several blockbuster acquisitions in recent weeks.
In an insightful post by Tom Zanki at Law360, we delve into what to expect at #JPM2024 and what the remainder of the year might have in store for us.
Here is why I am so bullish on #lifesciences in 2024:
With interest rate rises abated (and potentially three drops on the block for 2024), 2024 should be 'risk ON.'
A strong cohort of late stage biotechs marching through the clinic at speed.
Additionally, there's a robust backlog of #IPOs entering the market, indicating an open window, especially for life sciences.
Moreover, #BigPharma is motivated to replace an aging portfolio of molecules about to lose protection.
Read more here for a more detailed exploration of these trends and their implications.
Discover more about Louis Lehot and explore additional professional insights on his website https://louislehot.com
Explore Related Content:
